Introduction: Targeted therapies have significantly improved the prognosis of subsets of
patients with advanced non-small-cell lung cancer (NSCLC) harboring somatically activated …

Many decades in the making, immunotherapy has demonstrated its ability to produce
durable responses in several cancer types. In the last decade, immunotherapy has shown …

Opinion statement Non-small-cell lung cancer (NSCLC) remains the most common cause of
cancer-related death worldwide. Traditional cytotoxic agents and their attendant toxicities …

In the last few years, the introduction of novel immunotherapeutic agents has represented a
treatment shift for a subset of patients with non-small-cell lung cancer (NSCLC). Checkpoint …

Despite of recent development in the field of molecular targeted therapies, lung cancer is a
leading cause of cancer death in the world. Remarkable progress has been made recently …

Simple Summary In recent years there has been a trend towards an increase in the
proportion of non-small cell lung cancer patients diagnosed with localized stage instead of …

Introduction. Immunotherapy has become an increasingly important therapeutic strategy for
those with cancer, with phase III studies demonstrating survival advantages in melanoma …

Immunotherapy for non-small cell lung cancer (NSCLC) is incorporated increasingly in first
line treatments protocols. Multiple phase 3 studies have tested different medications …

Lung cancer is the leading cause of cancer mortality and non-small cell lung cancer
(NSCLC) accounts for more than 85% of all lung cancers. Platinum-based doublet …

Lung cancer, with non-small cell lung cancer (NSCLC) being the major type, is the second
most common malignancy and the leading cause of cancer-related death globally …